

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

PROF. BETSY FOXMAN (Orcid ID : 0000-0001-6682-238X)  
DR. ALEXANDER H. RICKARD (Orcid ID : 0000-0001-5915-4176)

Article type : JAM - Review Article

***In Vitro* Model Systems for Exploring Oral Biofilms: From Single-Species Populations to Complex Multi-Species Communities**

Ting L. Luo<sup>1</sup>, Michael E. Vanek<sup>1</sup>, Carlos Gonzalez-Cabezas<sup>2</sup>, Carl F. Marrs<sup>1</sup>, Betsy Foxman<sup>1</sup>, Alexander H. Rickard<sup>1\*</sup>

- 1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
- 2. Department of Cariology, Restorative Sciences and Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI, USA.

\*Corresponding author:  
Alexander H. Rickard, Ph.D.  
Associate Professor  
Department of Epidemiology,  
University of Michigan School of Public Health  
1415 Washington Heights  
Ann Arbor, MI. 48109  
Tel: 734-615-8491  
**Email:** [alexhr@umich.edu](mailto:alexhr@umich.edu)

**Running title:** *In vitro* oral biofilm model systems

**Abstract**

Numerous *in vitro* biofilm model systems are available to study oral biofilms. Over the past several decades, increased understanding of oral biology and advances in technology have facilitated more accurate simulation of intraoral conditions and have allowed for the increased generalizability of *in vitro* oral

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/jam.15200](https://doi.org/10.1111/jam.15200)

36 biofilm studies. The integration of contemporary systems with confocal microscopy and 16S rRNA  
37 community profiling have enhanced the capabilities of *in vitro* biofilm model systems to quantify biofilm  
38 architecture and analyze microbial community composition. In this review, we describe several model  
39 systems relevant to modern *in vitro* oral biofilm studies: the constant depth film fermenter, Sorbarod  
40 perfusion system, drip-flow reactor, modified Robbins device, flowcells, and microfluidic systems. We  
41 highlight how combining these systems with confocal microscopy and community composition analysis  
42 tools aids exploration of oral biofilm development under different conditions and in response to  
43 antimicrobial/anti-biofilm agents. The review closes with a discussion of future directions for the field of *in*  
44 *vitro* oral biofilm imaging and analysis.

## 45 46 **Introduction: Importance of *in vitro* model systems to the study of oral biofilms**

47 Microorganisms form dynamic multi-species biofilm communities on numerous surfaces in the human oral  
48 cavity (Marsh 2009). Over time, oral biofilms change in composition and architecture as component  
49 microbes interact with each other, the environment, and the host (Lamont et al. 2018). Oral biofilm  
50 communities can be extremely resilient; redeveloping rapidly after physical perturbations (e.g. brushing or  
51 flossing) and chemical treatments (e.g. application of mouthwash) (Marsh 2010). Furthermore, certain  
52 ecological and environmental conditions can alter the microbial composition and behavior of oral biofilm  
53 communities resulting in dental caries and periodontal disease (Aas et al. 2008; Peterson et al. 2013;  
54 Marsh 2018). Dental caries and periodontal disease are among the most prevalent of human diseases  
55 (Petersen et al. 2005) ranking 1 and 11 in a 2016 ranking of global health burden of 328 diseases (Vos and  
56 Collaborators 2017). In 2016, an estimated 2.44 billion people had active dental caries while about 750  
57 million suffered from periodontal disease worldwide (Vos and Collaborators 2017).

58  
59 While clinical studies are the gold standard for evaluating approaches to control oral biofilms, implementing  
60 such studies can be costly and logistically demanding (Martin-Kerry et al. 2015). By contrast, *in vitro* biofilm  
61 systems offer a relatively less challenging platform for exploratory, fundamental, and applied studies to  
62 close knowledge gaps in human oral biofilms prior to clinical studies. For example, *in vitro* biofilm model  
63 systems have been used to demonstrate how biofilm formation, succession, and/or architecture respond to  
64 environmental challenges (Kolenbrander et al. 2006; Hojo et al. 2009), and to evaluate candidate  
65 antimicrobials (Corbin et al. 2011). Many of the available *in vitro* biofilm systems can be adapted to  
66 simulate multiple *in vivo* conditions representative of the human oral cavity (Coenye and Nelis 2010; Yu et  
67 al. 2017). The closer the *in vivo* mimicry, the more generalizable the results gathered from *in vitro* model  
68 systems are likely to be.

69  
70 An additional advantage of *in vitro* model systems is the ability to alter one parameter at a time, thus  
71 providing a powerful strategy for studying how biofilms develop (Fernandez et al. 2017). These experiments  
72 can provide clues into how component species interact with each other within the oral cavity and enable the  
73 characterization of potential keystone pathogenic species in biofilm development (Hajishengallis et al.  
74 2012). For example, when considering investigations into understanding how oral species interact with one

75 another, using a two stage chemostat system and a defined ten species biofilm community, Bradshaw and  
76 colleagues showed the absence of the promiscuous coaggregating organism *Fusobacterium nucleatum*,  
77 resulted in significant changes in biofilm community representation (Bradshaw et al. 1998). Other examples  
78 of how *in vitro* model systems have been used in fundamental and applied oral biofilm research are  
79 detailed in Table 1.

80  
81 In this review we describe the relevance of *in vitro* biofilm models to oral health and disease research and  
82 provide a distillation of previously established models used to develop defined single-species, defined  
83 multi-species, and complex multi-species (i.e. microcosm) oral biofilms. We also focus on select biofilm  
84 models that can be integrated with confocal microscopy and 16S rRNA community profiling. This  
85 integration enables the study of biofilm growth under conditions representative of the oral cavity. A  
86 particular focus of discussion will be on biofilm models that are open (constant delivery of fresh media),  
87 multiple-throughput (allowing for concurrent side by side testing) and that use small volumes to conduct  
88 experiments. Furthermore, we discuss the impact and potential clinical relevance of *in vitro* oral biofilm  
89 model systems, their limitations, and future directions for *in vitro* oral biofilm model research.

### 91 **Past and Present: Oral *In Vitro* Biofilm Models**

92 From early oral biofilm models developed in the mid 1900's (Dietz 1943; Pigman et al. 1952), that followed  
93 from relatively primitive models in the late 19<sup>th</sup> century (Tang et al. 2003), and throughout the ensuing  
94 decades, newer conceptual designs improved upon their predecessors. From a historical perspective, *in*  
95 *vitro* oral biofilm studies using model systems can be characterized by transitions in foci from fundamental  
96 to applied studies within three main arenas: (1) understanding the development of single-species biofilms,  
97 (2) exploring environmental and cell-cell interactions in defined multi-species biofilms, and finally, (3)  
98 studies of complex multi-species biofilms. In each arena, fundamental studies of biofilm development  
99 provide the framework for applied studies, such as the effects of antimicrobial or anti-biofilm interventions,  
100 resulting in insights into the potential application to improving oral healthcare. It should be noted that there  
101 are fewer fundamental and applied *in vitro* periodontal disease models compared to cariogenic models,  
102 partly because of the increased complexity of simulating subgingival plaque (Walker and Sedlacek 2007;  
103 Velsko and Shaddox 2018). Research in multi-species (microcosm) biofilms has recently gained traction  
104 due to technological advancements and methodologies that enable investigators to measure biofilm  
105 outcomes such as community membership with 16S rRNA profiling and measuring biofilm architecture  
106 captured by a confocal microscope (Rudney et al. 2012; Fernandez et al. 2017).

107  
108 Among the earliest examples of *in vitro* oral biofilm model systems was an “artificial mouth” developed by  
109 Pigman and colleagues to study early carious lesions using extracted teeth (Pigman et al. 1952). This  
110 model was particularly notable because it was arranged vertically, and sterile media was drip-fed over an  
111 extracted human tooth inoculated with pooled human saliva and housed in an acrylic box. The media  
112 reservoir was positioned above the extracted tooth and media delivered with a hypodermic needle. This  
113 experimental setup focused on identifying conditions that favor cariogenesis; Pigman's model is arguably

114 an ancestor to contemporary drip-fed systems (discussed later in this review). From the 1950's to the  
115 1960's, many *in vitro* oral studies improved Pigman's artificial mouth system, by including an incubator  
116 cabinet and sterilization with ethylene oxide (Pigman et al. 1955; Pigman et al. 1962; Pigman and Newbrun  
117 1962). From a fundamental perspective, these studies linked common dietary sugars, e.g. glucose and  
118 sucrose, to cariogenicity. From an applied standpoint, anti-cariogenic effects of compounds and dentifrice  
119 slurries could be evaluated by treating tooth enamel with anti-caries agents concomitantly with conditions  
120 that would favor cariogenesis.

121  
122 Artificial mouth model variants have been used extensively over the years since the mid 1980's, most  
123 frequently by Sissons' group (Sissons et al. 1985; Sissons et al. 1991; Sissons et al. 2000). Their artificial  
124 mouth system, called the "Multiple-plaque Artificial Mouth" (MAM), was developed from designs by Russell  
125 and Coulter (Russell and Coulter 1975) and Dibdin and co-workers (Dibdin et al. 1976). The MAM is  
126 experimentally flexible and reproducible, and is compatible with computer-controlled systems (Sissons et  
127 al. 1991; Wong et al. 1994; Sissons et al. 2000). Contributions and advancements by Sisson's group and  
128 other research groups to the development of artificial mouth systems and oral biofilm research (and in  
129 particular, dental caries research) are described in further detail in an informative review by Tang and  
130 colleagues (Tang et al. 2003).

131  
132 From the 1960's onwards, investigators identified and characterized many key microbial species associated  
133 with oral diseases (Listgarten 1965; Keyes 1968; Gibbons and Fitzgerald 1969; Tanner et al. 1979).  
134 Consequently, biofilm model studies from the 1970s to present often focused on single-species surface-  
135 attachment/biofilm development or dual-species interaction studies using key microbial species (Russell  
136 and Coulter 1977; Noorda et al. 1986; Bos et al. 1996; Wright et al. 1997). For example, biofilm model  
137 systems have improved understanding of coaggregation. Notably, using an *in vitro* flowcell biofilm model  
138 that used 25% pooled human saliva as the sole nutrient source, Palmer and colleagues evaluated biofilm  
139 development by three species known to coaggregate with one another: *Streptococcus gordonii*,  
140 *Streptococcus oralis*, and *Actinomyces oris*. Independently, *A. oris* and *S. oralis* were shown to poorly form  
141 biofilms within the model system; however, dual-species cultures of *A. oris* and *S. oralis* formed more  
142 abundant biofilms (Palmer et al. 2001). The role of coaggregation in biofilm development has since been  
143 further explored, using *in vitro* biofilm models (Foster and Kolenbrander 2004; Nagaoka et al. 2008;  
144 Periasamy and Kolenbrander 2009).

145  
146 In part due to limitations with the ability to identify microorganisms in complex microcosm communities, as  
147 well as the interest in the behavior of specific oral pathogens/species, many studies in the 1990s and 2000s  
148 were restricted to the development of oral biofilms containing one or a few species. While single or small  
149 consortium biofilm model systems can play an important role in uncovering the behavior of individual or  
150 small groups of species (as mentioned above), studies of such communities provide limited understanding  
151 of how natural oral multi-species microbial communities function in their native environment (Rudney et al.  
152 2012). Natural oral biofilms exist as a dynamic ecosystem with estimates of the total number of indigenous

153 species ranging in the hundreds (Avila et al. 2009). In complex multi-species communities, the behavior of  
154 a single species can be modified by other species in a community to behave in a way distinct from its  
155 behavior when alone. Emphasizing this point, Sissons remarked in his review of oral biofilm model systems:  
156 “an attempt to explain plaque behavior based on the properties of monocultures can be regarded  
157 somewhat as heroic” (Sissons 1997). However, through broad technological advancements in the last  
158 decade, most notably advances in microscopy and 16S community profiling, investigators have acquired  
159 tools and methods to better characterize multi-species or microcosm biofilms (Tan et al. 2017). In recent  
160 years, many fundamental validation and protocol studies emerged to gauge reproducibility and provide  
161 preliminary microbiological results from *in vitro* oral microcosm biofilm (Edlund et al. 2013; Samarian et al.  
162 2014; Klug et al. 2016). Specifically, studies using *in vitro* oral microcosm biofilm models have enabled the  
163 measurement of different biofilm outcomes, such as biofilm architecture, microbial community profiles, and  
164 taxonomic spatial distribution (Luo et al. 2019; Roder et al. 2020).

165  
166 To provide historical context, this review describes *in vitro* model systems that have been developed and  
167 adapted over the last fifty years. Particular attention is given to selected drip-fed and flow-fed model  
168 systems which have been used in oral biofilm studies by various research groups (**Fig. 1**). Static  
169 microplate-based systems, which generally expose developing biofilms to minimal fluid flow, are not  
170 discussed as these types of biofilm systems were recently reviewed by Azeredo and colleagues (Azeredo  
171 et al. 2017). Drip-fed systems deliver nutrient semi-continuously, whereas flow-fed systems deliver a  
172 constant flow of nutrients. The drip-fed systems discussed are the constant depth film fermenter (CDFF),  
173 the Sorbarod perfusion system, and the drip-flow biofilm reactor. The flow-fed systems that are discussed  
174 are the modified Robbins device (MRD), flowcells, and microfluidic systems, of which we describe the  
175 Bioflux™ in detail. Many of these systems possess attributes that make them appealing candidates as  
176 model systems for modern oral biofilm studies. All the model systems discussed in this review are  
177 compatible to varying degrees with confocal microscopy and have or can conceivably be manipulated to  
178 harvest biofilm cells for microbial community profiling using culture-dependent techniques and/or modern  
179 culture-independent (next-generation sequencing) methods (**Fig. 1**). Finally, all systems can be set up for  
180 multiple-throughput studies, and some require only relatively small volumes for experiments. A summary of  
181 the discussed model systems is presented in **Table 2**.

### 182 183 **Advancements in *In Vitro* Model Systems for Oral Biofilm Research**

184 Over the years, *in vitro* biofilm models, including drip-fed and flow-fed model systems, have been modified  
185 to better reflect the characteristics of the oral environment. One particularly important modification replaced  
186 traditional bacteriologic culture medium with either artificial saliva such as, “McBain medium”, variations of  
187 “SHI medium” (McBain et al. 2005; Tian et al. 2010; Lamont et al. 2021), other artificial saliva types such as  
188 those highlighted by Pratten and colleagues (Pratten et al. 1998), or human saliva (Yaari and Bibby 1976;  
189 Palmer et al. 2001). Biofilms grown in artificial saliva or pooled human saliva will likely better represent *in*  
190 *vivo* plaque as the bacterial composition is influenced by selective pressure of the physical-chemical  
191 properties and nutrients of human saliva, rather than artificial media. Indeed, over 10 years of research

192 published by the Kolenbrander group using *in vitro* oral biofilm models has highlighted the utility of using  
193 pooled 25% human saliva as a growth medium to study complex interactions between oral bacteria in  
194 biofilms (Kolenbrander 2011).

195  
196 In addition to the relevance of growth medium composition, growth of biofilms under different shear is  
197 important for simulating salivary or gingival crevicular flow (Blanc et al. 2014; Fernandez et al. 2017). The  
198 composition of exhaled breath can also be mimicked by delivering a gas mixture consisting of 95%  
199 atmospheric air and 5% carbon dioxide (Dibdin et al. 1976). Lastly, the choice of a substratum that  
200 represents human enamel or dentin should be considered. Hydroxyapatite and glass are two surfaces  
201 commonly used to represent oral hard surfaces. While glass may seem to be less relevant than  
202 hydroxyapatite for oral biofilm studies, a study comparing the differences of *S. sanguinis* biofilm growth on  
203 both surfaces, on which an acquired pellicle (i.e. conditioning film) had also formed, found no difference in  
204 resultant biofilm development (Elliott et al. 2005). The authors concluded that the generation of a  
205 conditioning film reduced the influence of differences in substratum surface properties. Indeed, many  
206 papers have described the use of saliva (artificial or pooled human saliva) to “condition” glass surfaces to  
207 generate an acquired pellicle to enhance bacterial adhesion for subsequent biofilm studies (Foster and  
208 Kolenbrander 2004; Tsutsumi et al. 2016). With the development of *in vitro* biofilms that are increasingly  
209 representative of biofilms in the oral cavity, investigators will gain a better platform to observe the role oral  
210 biofilm plays in disease.

211  
212 Once an *in vitro* model system has been validated and optimized for a dental biofilm study, the cost to  
213 maintain the system and serially perform multiple runs decreases significantly. Compared to *in vivo* based  
214 research (Martin-Kerry et al. 2015) proof of concept and testing for efficacy of new anti-biofilm agents  
215 through *in vitro* model systems will likely be time and cost effective. Another advantage of using *in vitro* oral  
216 biofilm models is that oral biofilm communities can be relatively easily developed. *In vitro* systems can be  
217 extremely versatile: nutrient availability, flow, the introduction of defined species, and time can be  
218 strategically controlled to help answer specific research questions regarding biofilm architecture, cellular  
219 organization, and mechanisms associated with biofilm growth (Roder et al. 2020).

## 221 **Drip-fed Biofilm Models**

### 222 **Constant Depth Film Fermenter**

223 The constant depth film fermenter (CDFF) was first described by Peters and Wimpenny in 1988 as a means  
224 to develop freshwater biofilms at a defined thickness (Peters and Wimpenny 1988). The reason for  
225 maintaining biofilms at a constant depth is to achieve a steady state biofilm within a reactor where  
226 measurable properties do not change significantly over time (Kinniment et al. 1996). Mechanically, the  
227 CDFF is a chamber housing a rotating turntable on the bottom (for a graphical representation, see McBain,  
228 2009). The rotating turntable holds customizable sampling pans where each pan contains plugs made of a  
229 material on which biofilms develop. To distribute media to each plug, media is drip-fed from above via inlets  
230 as the disc rotates. Spent media is collected in a waste outlet located below the disc. The CDFF keeps

231 biofilms at a constant depth using a scraper blade that removes excess biofilm biomass and spent media  
232 as the disc rotates. The initial model described by Peters and Wimpenny held 25 plugs to support biofilm  
233 development (Peters and Wimpenny 1988) while later models had the capacity of up to 75 plugs (Deng et  
234 al. 2005).

235  
236 While initially used to study freshwater biofilms (Peters and Wimpenny 1988), the CDFD has been applied  
237 successfully to the development of *in vitro* oral biofilms (McBain 2009; Hope et al. 2012). The CDFD has  
238 been used extensively for single-species (Zanin et al. 2005; Metcalf et al. 2006), defined consortia (Fan et  
239 al. 2012), and oral microcosm studies (Hope et al. 2002; McBain et al. 2003; Abdulkareem et al. 2015).  
240 CDFDs are particularly well-equipped to conduct studies of antimicrobial challenges on mature oral biofilms,  
241 and for monitoring the growth of biofilms. Biofilm can be grown on the plugs in the same chamber and  
242 assigned to treatment or control groups during or post-growth. Specifically, plugs can be removed from the  
243 device and then treated (Hope et al. 2002) or treatment(s) can occur while the plugs are within the device  
244 (Deng et al. 2005). For example, Deng and colleagues grew *S. mutans* on dentin plugs in a split CDFD  
245 chamber that was simultaneously treated with sodium fluoride or sodium fluoride/chlorhexidine formulations  
246 after the biofilm had matured (Deng et al. 2005). Sodium fluoride/chlorhexidine formulations conferred the  
247 greatest kill, lactic acid reduction, and remineralization of dentin compared to sodium fluoride alone. In  
248 another study, Feldman and coworkers monitored dual-species *C. albicans* and *S. mutans* biofilm  
249 development on pre-treated hydroxyapatite discs (Feldman et al. 2017). The discs were coated with a  
250 membrane designed to slowly release thiazolidinedione-8, a quorum sensing quencher. Biofilm  
251 development was hindered on discs containing the quorum sensing quencher. When considering these and  
252 other papers using the CDFD, it has been, and still is, a valued *in vitro* model system to study oral biofilms.

### 254 **Sorbarod Perfusion System**

255 In the mid 1990's, Hodgson and colleagues developed a perfused *in vitro* model system that was called the  
256 Sorbarod perfusion system (also referred to as a Sorbarod biofilm fermenter system) (Hodgson et al. 1995).  
257 There are multiple structural variations of this system that have been published, but all use Sorbarod filters  
258 as the material on which biofilms develop. Sorbarod filters are cylinders that contain a roll of cellulose fibers  
259 and the cylinders are approximately 10mm in diameter and 20 mm in length (Budhani and Struthers 1997;  
260 McBain 2009). Sorbarods can be loaded into supports such as tubing (Hodgson et al. 1995), syringes  
261 (Rickard et al. 2008), or an engineered device that can support multiple Sorbarods (McBain et al. 2005),  
262 and exposed to flowing media. Harvested Sorbarods can be used to perform viable counts and biofilms on  
263 the Sorbarod fibers can be imaged. Another benefit of this model system is the high surface area to volume  
264 ratio, which maximizes the amount of biofilm that can form. During an experiment, gas or fluid can be  
265 collected to track cell numbers, volatile sulfur compounds, and cell-signaling molecules (Hodgson et al.  
266 1995; Spencer et al. 2007; Rickard et al. 2008).

267  
268 A Sorbarod perfusion system can be used for anaerobic and microcosm biofilm studies which require  
269 extended run times to achieve dynamic steady states (McBain 2009). In a study by McBain and colleagues

(McBain et al. 2005), multiple Sorbarod devices were inoculated with saliva from human volunteers and supplied with artificial saliva nutrient. Dynamic stability was achieved after two to three days, with high bacterial diversity and presence of anaerobic species. McBain and coworkers concluded that the Sorbarod system was effective at maintaining a stable and reproducible oral biofilm community over multiple days (McBain et al. 2005). In an oral malodor study by Spencer and colleagues, a microcosm derived from dorsal tongue scraping was used as inoculum to grow representative communities that produce volatile sulfur compounds (Spencer et al. 2007). Biofilm development was studied over 96 hours and quasi steady states were achieved by 48 hours. The community composition of developed biofilms resembled that of the original dorsal tongue scrapings. Overall, Spencer and colleagues demonstrated the viability of the Sorbarod system for maintaining a stable tongue microcosm community.

### **Drip-Flow Biofilm Reactor**

The drip-flow biofilm reactor was first described by Xu and colleagues in the late 1990's as a means to develop *P. aeruginosa* biofilms (Xu et al. 1998). Unlike the CDFR and Sorbarod systems, the drip-flow biofilm reactor is unique in that it is positioned at an angle and media is dripped from above at the apex of the reactor. During use, the media flows downward coating a glass microscope slide or a detachable coupon. The coupon can be made from various materials, allowing investigators the flexibility of choosing a substratum on which a biofilm can develop (Gomes et al. 2018). The gravity-assisted flow of media creates a low shear environment that can be adjusted by elevating or depressing the angle of the system. At the bottom of the reactor is an outlet where effluent media traverses into a waste receptacle. An excellent review with informative diagrams and detailed descriptions of the use of drip flow biofilm reactors is presented by Goeres and colleagues (Goeres et al. 2009). When considering analysis of biofilms developed in the system, care must be applied in sampling biofilms over a large surface area whether it be imaging or harvesting biomass for further testing. As demonstrated by Xu and colleagues, oxygen availability can influence heterogeneity of *P. aeruginosa* biofilms and if media flow across the slide is not uniform, then the development of a heterogeneous biofilm is possible (Xu et al. 1998).

Several studies have used the drip flow reactor to model single-species and multi-species oral biofilms. For example, two single-species studies used the drip flow reactor to test the efficacy of antimicrobial agents on *S. mutans* biofilm development (Brambilla 2017; Williams et al. 2017) Williams and colleagues used silver loaded into polymethyl methacrylate (PMMA) sheets, which were cut into rectangular coupons; Brambilla and colleagues used chlorhexidine loaded into dentin bonding systems. Williams and colleagues demonstrated that silver PMMA coupons were able to resist *S. mutans* biofilm formation in short-term washouts, but not long-term washouts. As described by Brambilla and colleagues, chlorhexidine loaded dentin adhesion bonding agents demonstrated variable results, leading authors to suspect the variable chemical composition of the dentin binding systems masked the effects of chlorhexidine. Drip flow reactors have also been used for dentifrice studies on mature oral multi-species microcosm biofilms (Ledder et al. 2010; Ledder and McBain 2012). In those studies, oral microcosm biofilms were grown over 24 or 48 hours,



308 followed by treatment regimens delivering dentifrice slurries every six hours for six days. The dentifrice  
309 treatments reduced culture counts and affected oral biofilm community alpha diversity.

## 311 **Flow-fed Biofilm Models**

### 312 **Modified Robbins Device**

313 Based on an earlier design called the Robbins device, the modified Robbins device (MRD) (McCoy et al.  
314 1981), facilitates the study of biofilms under flow. The MRD uses individual coupons affixed to plugs that  
315 then can be inserted into ports that run along the length of a device. The coupons can be made of different  
316 materials such as those used in dental prostheses or hydroxyapatite (Blanc et al. 2014). A peristaltic pump  
317 provides unidirectional media flow across all ports after coupons are inoculated. Biofilm development  
318 occurs on the surfaces of the coupons as the system runs. Plugs containing coupons can be removed  
319 aseptically over time and replaced with plugs containing fresh coupons. The number of sampling ports of  
320 the MRD varies by design. For example, commercially available low pressure and small volume MRDs are  
321 available that range from 12-25 ports. Thus, longitudinal studies of biofilms can be performed, although, as  
322 with the CDFR, Sorbarod system, and the drip-flow biofilm reactor, it is not possible to perform repeated *in*  
323 *situ* biofilm visualizations of the same biofilm sample over time and only endpoint imaging can be  
324 performed (**Fig. 1**). Coupons with the supporting plug and associated biofilm must be removed to be  
325 visualized microscopically.

326  
327 The MRD has been used extensively to study oral biofilms, with many studies demonstrating its  
328 reproducibility at developing oral biofilms (Honraet and Nelis 2006; Coenye et al. 2008; Noiri et al. 2008;  
329 Sliepen et al. 2010; Blanc et al. 2014; Yassin et al. 2016). The system and its detachable coupons proved  
330 to be particularly useful in evaluating the efficacy of antimicrobials and materials primed with antimicrobial.  
331 For example, in the study by Yassin and colleagues (Yassin et al. 2016), MRD coupons were prepared  
332 from a mixture of polymethyl methacrylate and sodium fluoride to create a copolymer that can be used for  
333 dentures while also releasing fluoride ions passively while worn. The investigators observed that three-  
334 species (*C. albicans*, *L. casei*, *S. mutans*) biofilm growth was inhibited by 10-fold on coupons containing the  
335 fluoride compared to biofilm growth on coupons that did not. Conversely, biofilm can be treated after biofilm  
336 development to evaluate effectiveness of an antimicrobial (Coenye et al. 2008). In 2008, Coenye et al. grew  
337 mono-species biofilms of *C. albicans*, *S. mutans*, *S. aureus*, and *P. aeruginosa* in a stainless steel MRD.  
338 After growth, the biofilms were treated with NitrAdine™, sonicated to remove biofilm from the coupons, and  
339 plated to determine efficacy of treatment in preventing regrowth. Similarly, Blanc *et al.* developed multi-  
340 species biofilms on hydroxyapatite coupons to test antimicrobial efficacy of chlorhexidine, cetylpyridinium  
341 chloride, and sodium fluoride mouthwash rinses (Blanc et al. 2014).

### 343 **Flowcells**

344 Of the six model systems described in this review, flowcells are among the smallest in physical size (**Table**  
345 **2**). Due to the compactness of the system, flowcells use small volumes of inocula and media for biofilm  
346 experiments. Oral biofilms can be studied at the end of an experiment using a confocal microscope

347 (endpoint studies, for example by Foster et al., 2004) or at different times, for example during treatment  
348 with antimicrobials (Corbin et al. 2011) (**Fig. 1**). An example of a flowcell system built in-house for oral  
349 biofilm studies was described by Palmer & Caldwell in the mid-1990s (Palmer and Caldwell 1995). The  
350 main advantage of using flowcells to study oral biofilms is the capability of studying changes to biofilm  
351 community composition and architecture over time (Fig. 1). For imaging, this can be accomplished because  
352 the substratum of the flowcell is often glass. Using confocal or even epifluorescence microscopy (for less-  
353 detailed studies), the accumulation of biofilm biomass can be monitored at different times following  
354 inoculation.

355  
356 The flowcell has played a prominent role in oral biofilm research. For example, in 2004, Foster and  
357 colleagues used flowcells to test the efficacy of antimicrobials on oral biofilms. The authors grew single  
358 species *S. gordonii* biofilms in saliva-conditioned flowcells and treated them with commercially available  
359 mouthwashes (Foster et al. 2004). The study indicated that different active ingredients within mouthwashes  
360 differed in antimicrobial efficacy. Later, Foster and colleagues used the same type of saliva-conditioned  
361 flowcells for consortia biofilms containing four oral species and showed that biofilm formation can depend  
362 on whether the microorganisms form coaggregates with each other in the planktonic phase (Foster and  
363 Kolenbrander 2004). The flowcell has also been used in studies to test pellicle formation on glass  
364 compared to hydroxyapatite. Elliott and colleagues showed that the two surfaces were similar and had no  
365 effect on biofilm attachment (Elliott et al. 2005). Another study used flow cells to image in real-time biofilm  
366 development of the oral pathogen *Candida albicans* (McCall and Edgerton 2017). McCall and Edgerton  
367 compared wild type and hyperfilamentous  $\Delta hog1$  *C. albicans* strains in their ability to attach to the flow cells  
368 and develop biomass during the 18-hour growth. The gene *hog1* is activated by oxidative stress, osmotic  
369 stress and heavy metal stress resulting in hyphal filamentation (Su et al. 2013). McCall and Edgerton  
370 demonstrated that the wild type *C. albicans* had twice the attachment rate of the  $\Delta hog1$  mutant, but formed  
371 biofilms of lesser biomass, suggesting that cellular detachment is integral for biomass accumulation.

### 372 373 **Microfluidic Model Systems**

374 Microfluidics involves the engineered delivery of fluids on the sub-milliliter levels through microchannels  
375 (Sackmann et al. 2014). A significant advantage of *in vitro* microfluidics systems over other *in vitro* model  
376 biofilm systems is the much smaller amounts of inoculum that are needed (Samaritan et al. 2014). This is  
377 especially advantageous if sample volume is limited or reagents are expensive. Additionally, the systems  
378 are compact and require low energy costs to run. Microfluidic biofilm model systems have become  
379 increasingly popular in oral biofilm studies as they can be used to perform culturing, bioinformatics, and  
380 microscopy (Gashti et al. 2016; Mira 2018).

381  
382 One commercially available microfluidic system is the Bioflux™ system, manufactured by Fluxion  
383 Biosciences (San Francisco, CA). The Bioflux™ is a continuous flow microfluidic system used by  
384 investigators to model oral biofilms (Tao et al. 2011; Ding et al. 2014; Volgenant et al. 2016). The system  
385 consists of three main parts: consumable microfluidic plates, a controller, and a software control interface

386 (Samarian et al., 2014). The software control interface regulates the flow rate, the total runtime,  
387 and determines which pumps are active. A pressure top that is fixed to the top of the consumable  
388 plates creates an airtight environment within the Bioflux™ plate, allowing pressure to be applied only from  
389 the controller. This forces fluid from inlet well to output well at a fixed rate. A viewing port exists between  
390 the inlet and outlet wells, where biofilms develop under the prescribed flow rate. The Bioflux™ plate, similar  
391 to flowcells, can be imaged with inverted microscopy techniques during biofilm growth or after maturation  
392 (Fig. 1).

393  
394 Of all the systems described in this review, the Bioflux™ requires the least amount of media and inocula.  
395 Oral biofilms have been developed overnight at 0.2 dynes/cm<sup>2</sup>, requiring 380 uL of media per sample and  
396 as little as 50 μL of inoculum. Volumes required were calculated from the Bioflux™ software interface. The  
397 low volumes required are especially advantageous for studies using donations of bodily fluid for media  
398 and/or inoculum. Another advantage of the Bioflux™ system is its throughput. With evenly-distributed flow  
399 supplied by a computerized pneumatic pump and a heating plate that covers the entirety of the plate,  
400 multiple biofilms can be produced in parallel under the same environmental parameters. Additionally, the  
401 atmospheric composition of the airtight environment within the Bioflux™ can be controlled by fitting  
402 a Bioflux™ controller with a pressurized gas cylinder containing a defined gaseous mixture. Different plate  
403 formats contain 3, 8, or 24 channels which enable replicates of oral biofilms to be developed in parallel.  
404 Given the dimensions of the Bioflux™ plates, which are compatible with microplate holders, both endpoint  
405 and live imaging of oral biofilm development is possible (Fig. 1).

406  
407 First described in 2010, Benoit and coworkers used the throughput advantage of the Bioflux™ system to  
408 screen the effectiveness of several antimicrobials on *P. aeruginosa* PAO1 biofilms (Benoit et al. 2010).  
409 Over the last decade, the Bioflux™ system has been adapted for oral biofilm architecture and community  
410 studies (Ding et al. 2010; Dong et al. 2012; Samarian et al. 2014; Fernandez et al. 2017). In 2013, Nance  
411 and coworkers developed overnight microcosm biofilms seeded from salivary inoculum and tested the  
412 antimicrobial effectiveness of cetylpyridinium chloride (CPC) (Nance et al. 2013). Using LIVE/DEAD™  
413 staining, a dose-response viability gradient was observed between .001% and .5% w/v CPC. Also, in the  
414 study, Nance and coworkers established that the Bioflux™ system was capable of developing an oral  
415 biofilm that was compositionally similar to early supragingival plaque. A standardized protocol for  
416 developing oral multi-species biofilms using the Bioflux™ system was described by Samarian et al. in 2014.  
417 The Bioflux™ system also has been used to study the effects of different antimicrobial compounds on oral  
418 biofilms. For example, Luo et al. evaluated the effect of stannous fluoride on oral multi-species biofilm  
419 architecture (Luo et al. 2019). Lastly, the Bioflux™ system has been used in single-species studies. Ding  
420 and coworkers grew single-species *S. mutans* biofilms with flowing media and tested the antimicrobial  
421 peptide bactenecin (Ding et al. 2014). The authors observed a significant decrease in viability. In another  
422 study using the Bioflux™, Dong et al. showed that development of *S. mutans* biofilms in subminimum  
423 inhibitory concentrations of chlorhexidine or sodium fluoride altered the biofilm architecture and

424 development in subminimum inhibitory concentrations of tea polyphenols reduced biofilm biomass (Dong et  
425 al. 2012).

### 426 **Integration of *In Vitro* Oral Model Systems with Microscopy and Bioinformatics**

427 Since the first biofilm model systems were described in the 1950s, innovations in methodologies have  
428 enhanced the generalizability of oral biofilms grown *in vitro*. Today, investigators can cultivate an *in vitro*  
429 oral biofilm that is compositionally similar to the microbial community of plaque (Rudney et al. 2012; Nance  
430 et al. 2013). The ability to generate representative communities is critical if the desired outcome is to  
431 generalize results to human subjects. Two disciplines where technological advancements have significantly  
432 augmented the value of laboratory model systems are microscopy and bioinformatics, particularly in the  
433 domain of 16S rRNA bacterial community profiling. Microscopy is essential for the study of biofilm  
434 architecture, whereas bioinformatics techniques are becoming increasingly popular for characterizing the  
435 taxonomic diversity and function of biofilm microbial communities as a whole.

### 437 **Confocal Microscopy**

438 Several different microscope technologies are available to study oral biofilms each with advantages and  
439 disadvantages. While not the focus of this review, a useful review of microscopy and image analysis has  
440 been published by McNamara and colleagues (McNamara et al. 2017). Here, we will focus on the use of  
441 the confocal microscope, which was first used to describe biofilms in 1991 (Lawrence et al. 1991). Using a  
442 confocal microscope, investigators can capture oral biofilm architecture and simultaneously gain insight into  
443 cell viability or species location (Zaura-Arite et al. 2001; Cuadra-Saenz et al. 2012; Ruangcharoen et al.  
444 2017). Instead of destructively removing oral biofilm for downstream quantification, confocal microscopy  
445 enables *in situ* quantification by taking optical sections of a biofilm and subsequently generating 3D  
446 renderings using the optical sections. This can be performed for single-species biofilms, a defined multi-  
447 species consortium, or complex microcosm biofilms. For example, instead of culturing and harvesting  
448 biofilm to determine colony forming units (CFU), a confocal microscope can take a digital snapshot of a  
449 biofilm stained with viability stains (e.g. a mixture of SYTO-9 stain and propidium iodide stain, which are  
450 part of the commercially available LIVE/DEAD™ staining system). In this scenario, the amount of viable  
451 (membrane intact) and inactive/dead (membrane compromised) cells or biofilm biomass can be quantified  
452 while the biofilm remains attached to the substratum. This approach has advantages because determining  
453 CFUs may underestimate true viability due to the destructive nature of the biofilm harvesting process  
454 and/or inadequate cell removal from the surface. However, it should be noted that the use of viability stains  
455 is not without potential problems which include possible issues with differential staining (Netuschil et al.  
456 2014).

457  
458  
459 A key advantage of confocal microscopy over other forms of microscopy, is the ability to discern complex  
460 biofilm architecture, the properties of the contained cells, and spatial arrangement of biofilm species. In  
461 non-targeted (i.e. non species-specific) fluorescence studies, confocal microscopy has been used to  
462 identify distribution of viable and non-viable cells in multi-species oral microcosm biofilms developed within

463 a CDFF (Hope et al. 2002). Using LIVE/DEAD staining, Hope and colleagues demonstrated that the basal  
464 layer of an untreated oral multi-species biofilm contained more non-viable cells compared to the surface. In  
465 targeted (i.e. species-specific) fluorescence studies, the spatial position of a specific species within a multi-  
466 species biofilm can be determined (Palmer et al. 2001; Thurnheer et al. 2019). For example, Robert  
467 Palmer and coworkers used fluorescently-labeled antibodies to discern the spatial arrangement of oral  
468 *Streptococcus gordonii*, *Streptococcus oralis*, and *Actinomyces oris* in single-species and dual-species  
469 biofilms developed in pooled human saliva (Palmer et al. 2001). These biofilms were grown in flowcells  
470 where the only potential perturbation to the biofilms was from labeling with antibodies after growth. Another  
471 notable study using an *in vitro* model system and confocal microscopy was performed by Thurnheer and  
472 colleagues who grew biofilms containing six species on hydroxyapatite disks in 24-well polystyrene cell  
473 culture plates and used fluorescent in situ hybridization (FISH) to discern their spatial arrangement  
474 (Thurnheer et al. 2019). This work showed that FISH, in combination with the optical sectioning capabilities  
475 of a confocal microscope, enabled the analysis of spatial arrangement of numerous species and had the  
476 potential to investigate alterations in biofilm species arrangement in response to environmental challenges.  
477 Understanding these biofilm structures and cellular arrangements could be important to biofilm control.  
478 Thus, considerable effort has been dedicated to identifying a disease-associated motif seen in biofilm  
479 architecture and its possible role in pathogenesis. With this in mind, a recent paper by Kim and colleagues  
480 identified corona-like biofilm architectures formed by when *S. mutans* developed biofilms with other oral  
481 species and these architectures could enhance the pathogenic potential of *S. mutans* in biofilm  
482 communities (Kim et al. 2020).

483  
484 With modification, certain *in vitro* model systems can be adapted to monitor changes in biofilm architecture  
485 over time (Fig. 1). To image a developing biofilm over time, the model system must be capable of growing  
486 an oral biofilm on a surface that can be simultaneously imaged with microscopy techniques as the system  
487 is running. Indeed, a recent study by Paula and coworkers explored the dynamics of *S. mutans* biofilm  
488 formation from microcolonies to biofilm superstructures (Paula et al. 2020). Using a modified flow cell that  
489 can house hydroxyapatite discs containing attached *S. mutans*, biofilm development was monitored with a  
490 confocal microscope taking images every 20 minutes.

491  
492 To maximize information derived from imaged *in vitro* biofilms, the application of appropriate downstream  
493 computational analytics is required to describe the spatial position of fluorescently labeled biofilm species.  
494 Many analytical software packages are publicly available and offer a multitude of outcome measures.  
495 Alternatively, customized in-house analysis can be performed. A computing environment such as MATLAB  
496 (Natick, MA, USA) is necessary for the latter alternative and its successful implementation is described in  
497 more detail by Beyenal and colleagues (Beyenal et al. 2004). Furthermore, the commonly used biofilm  
498 image analysis program COMSTAT, which was originally coded in MATLAB (Heydorn et al. 2000), provides  
499 users a graphical user interface to analyze confocal data. A more recent analytical tool built using the  
500 MATLAB environment is the Biofilm Architecture Inference Tool (BAIT), developed by Luo and colleagues  
501 (Luo et al. 2019). BAIT can import confocal image stack data and perform various image thresholding

502 algorithms prior to image analysis. One method, named the biovolume elasticity method (BEM), identifies  
503 thresholds that more accurately define biofilm edges (Luo et al. 2018). Post-processed image stacks can  
504 then be quantified for various architectural descriptors including: biovolume, surface area, fluffiness, total  
505 number of objects, connectivity, and convex hull porosity. Viability can also be evaluated if the confocal  
506 stack possesses two channels. For combining optical sections collected by confocal microscopy and the  
507 subsequent image rendering of biofilms, commercially available software, such as Imaris (Zurich,  
508 Switzerland) and Volocity (Puslinch, Ontario), can be used to give further insight into architectural features  
509 of oral biofilms. Open-source software imaging programs software such as ICY (de Chaumont et al. 2012)  
510 and BioimageXD (Kankaanpaa et al. 2012) are also available to render biofilms from confocal image  
511 stacks.

### 512 **16S rRNA Community Profiling**

513 Since its inception in the 1970's, 16S rRNA gene sequencing technology has become extremely useful in  
514 studying bacterial phylogeny and taxonomy (Woese and Fox 1977; Weisburg et al. 1991; Konstantinidis  
515 and Tiedje 2007). Given that all bacteria possess and require the 16S rRNA gene, it is an excellent target  
516 for identifying and analyzing community membership (Clarridge 2004; Aas et al. 2005; Petti et al. 2005).  
517 Furthermore, 16S rRNA sequences from bacterial species are readily available on public and curated  
518 repositories such as GenBank, Greengenes, RDP, and SILVA for comparative sequence analyses  
519 (Balvociute and Huson 2017; Benson et al. 2018). Depending on the length of the 16S rRNA gene  
520 sequence that is analyzed and the variable regions covered, for which there are nine "hypervariable  
521 regions" (labelled V1 – V9) in the 16S rRNA gene, identities can be assigned to a taxonomic rank often to  
522 the genus or species level (Chakravorty et al. 2007; Janda and Abbott 2007). With more hypervariable  
523 regions sequenced within a read a higher resolution taxonomic assignment can be achieved. Prior to the  
524 advent of next-generation sequencing (NGS), investigators relied upon culture-dependent techniques, such  
525 as culturing on agar to isolate bacteria for identification, or older culture-independent (molecular)  
526 technologies (e.g. Sanger sequencing of cloned 16S rRNA gene sequences or denaturing gradient gel  
527 electrophoresis) that produced relatively low read counts of 16S rRNA sequences and/or limited species  
528 resolution for *in vitro* oral microcosm biofilm studies (**Fig. 1**). With NGS, massively parallel and deep  
529 sequencing capabilities have emerged, enabling the oral microbiome to be quickly characterized (Behjati  
530 and Tarpey 2013).

531  
532  
533 The development of NGS and endeavors to study increasingly more complex *in vitro* oral biofilm  
534 microcosms has also coincided with a shift in the focus on the pathogenicity of oral biofilms from individual  
535 species associated with disease to understanding the disease-causing ability of microbial communities (Li  
536 et al. 2016; Vogtmann et al. 2018). Substantial evidence indicates that multiple species, and their  
537 interactions with the host and one another, are responsible for propagating pathways for soft and hard  
538 tissue destruction seen in periodontal disease and caries (Negrini et al. 2019; Wade and Prosdocimi 2020).  
539 For instance, Whitmore and Lamont reviewed the role mitis group streptococci play in the recruitment of  
540 successional pathogenic species such as *Porphyromonas gingivalis* and *Actinobacillus*

541 *actinomycetemcomitans* (Whitmore and Lamont 2011). Another review by Banas and Drake, emphasized  
542 the perspective shift away from *S. mutans* being the lone causative agent to caries, but rather a relative  
543 contributor within a complex oral microbiome (Banas and Drake 2018). Thus, the present challenge is to  
544 identify microbial community profiles, not individual species, most associated with disease.

545  
546 Pertinent to this review, the incorporation of NGS approaches with biofilm model systems is relatively new  
547 and there are a variety of factors and challenges that must be considered when considering NGS studies of  
548 *in vitro* biofilm model systems. Critically, there have been numerous NGS platforms used for the 16S rRNA  
549 profiling of biofilm communities. Choice of sequencing platform depends on the investigator's research  
550 questions and involve trade-offs between read length, read depth, sequencing depth, and accuracy.  
551 Sequencing platforms relevant to oral biofilm studies are listed below in **Table 3**, although this is not an  
552 exhaustive list since NGS technologies that offer insufficient or unnecessary read length (e.g. 20Kb read  
553 lengths offered by PacBio) for 16S rRNA gene sequencing are excluded. The choice of sequencing  
554 platform heavily influences which hypervariable regions can be included in one contiguous read. The longer  
555 the read length, the more hypervariable regions can be included. Some platforms offer paired-end reads  
556 (**Table 3**), which can be joined to create a longer fragment, but a trade-off between read-length and  
557 sequence overlap for accuracy must be considered. Hypervariable region selection can also influence  
558 interpretation of results and taxonomic resolution (Barb et al. 2016; Teng et al. 2018; Bukin et al. 2019).  
559 This consideration is accentuated for oral streptococci where species are difficult to differentiate due to the  
560 limited amount of variation in the hypervariable regions of the 16S gene (Mukherjee et al. 2018).

561  
562 When considering the collection of biofilm material to analyze the community composition of an oral biofilm  
563 grown *in vitro*, investigators must first harvest and prepare biofilm cells from their model system to be  
564 analyzed with NGS technologies. This process will vary by model system and may involve using physical  
565 treatments to harvest biofilm cells. For example, in the Bioflux™ system, this involves removing biofilm  
566 material from substratum with high shear (Samarian et al. 2014). With the modified Robbins device (MRD),  
567 sonication could be used to remove biofilm cells from coupons (Coenye et al. 2008). Unlike cell culturing  
568 techniques, the destructive nature of removing biofilm is less of a concern for 16S rRNA community  
569 profiling. Ultimately, the objective is to retrieve a cross-sectional snapshot of the oral biofilm community  
570 composition at the time of harvesting.

571  
572 Several oral biofilm studies have utilized NGS technologies to characterize the microbial community within  
573 biofilms that were developed using *in vitro* model systems. Velsko and Shaddox described a static system  
574 where they collected plaque samples from healthy and periodontitis-affected individuals (Velsko and  
575 Shaddox 2018). Plaque samples were used to inoculate hydroxyapatite discs and grown statically over  
576 eight days. The resultant communities were sequenced with Illumina MiSeq and characterized with the  
577 software QIIME (Caporaso et al. 2010; Velsko and Shaddox 2018). They concluded that periodontitis-  
578 derived plaque resulted in communities that differed from communities derived from healthy individuals'  
579 plaque samples, as determined by weighted UniFrac measures. In another study, Klug et al. used 454

580 pyrosequencing to determine community diversity and survivorship after enamel-dentin slabs worn by  
581 volunteers were removed and placed in biofilm reactors (Klug et al. 2016). They discovered general  
582 survivorship of the biofilm community and diversity was maintained from after removal to 48 hours after  
583 growth in the biofilm reactor. Fernandez and colleagues studied the effect of shear force on oral  
584 communities derived from saliva, tongue, and plaque-based inoculum (Fernandez et al. 2017). After  
585 harvesting biofilm communities grown in a microfluidics *in vitro* model system, the samples were sequenced  
586 with Ion Torrent sequencing platform. The group discovered that after overnight growth, bacterial  
587 communities shifted to a community with less alpha diversity compared to its starting inoculum. Taken  
588 together, these studies highlight the application of different NGS technologies and demonstrate its  
589 relevance in various *in vitro* oral biofilm model system studies.

### 591 **Concluding Remarks and Future Directions**

592 The miniaturization of *in vitro* platforms operating on the microscale, combined with integration with imaging  
593 and 'omic' technologies, as well as a greater understanding of the biology of oral biofilms have  
594 reinvigorated the appeal of laboratory biofilm model systems. A PubMed search using the search terms "*in*  
595 *vivo* model system oral biofilm" and "*in vitro* model system oral biofilm" indicates that laboratory-based  
596 models are more commonly used in the realm of oral biofilm research than animal-based models. This  
597 observation has held steady in the last 25 years. This popularization of laboratory-based systems is likely  
598 owed to technologies that can be tethered to model systems, such as confocal microscopes (Valm et al.  
599 2012) and 16S community profiling approaches (Azevedo et al. 2009). Combined with decreasing costs, *in*  
600 *vitro* biofilm model systems have become an appealing option for multi-species oral biofilm studies.

601  
602 The future directions of *in vitro* model systems could involve a shift from developing representative dental  
603 plaque within the system to transplanting already-developed *in vivo* plaque into the system. For example,  
604 Fernandez and coworkers described a cariogenic model using *ex situ* methods that involve human  
605 participants wearing non-invasive oral prostheses housing enamel specimens (Fernandez et al. 2016). *In*  
606 *vitro* model systems could also incorporate a biological substratum for biofilm development, such as that  
607 developed using tissue culture techniques.

608  
609 There are multiple surfaces in the intraoral cavity including hard and soft palate, tongue, subgingival,  
610 buccal, and teeth. Glass and hydroxyapatite are representative of the hard surfaces of teeth, but are a poor  
611 model for attachment and development of subgingival plaque (Cieplik et al. 2019). There is a disparity in  
612 volume of research involving epithelial substratum in oral diseases, thus periodontal biofilm models are  
613 lacking (Walker and Sedlacek 2007). This is due to the relative difficulty of cell culture techniques over use  
614 of glass or hydroxyapatite. Epithelial cells are the preferred substratum for periodontal models as they more  
615 adequately represent the substratum of subgingival plaque (Guggenheim et al. 2009). As demonstrated by  
616 Guggenheim and colleagues, an epithelial substratum can actively model the interaction between host  
617 immune cells and oral microbial biofilm cells. This is important to consider in periodontal models where *in*



*in vivo* microbial cells at the periodontal tissue interface trigger host immune response and then mount evasion or defense mechanisms.

Outcomes	Fundamental Study (Reference)	Applied Study (Reference)	Model System(s) Used
Cariogenesis*	D-glucose and sucrose induce caries (Pigman et al. 1962).	Fluoride slurry inhibits enamel softening (Pigman and Newbrun 1962).	Artificial Mouth
Single-Species Biofilm	<i>S. mutans</i> biofilms fed sucrose induces caries (Deng and ten Cate 2004).	Chlorhexidine in dentin bonding systems may inhibit <i>S. mutans</i> biofilm formation (Brambilla 2017).	Constant Depth Film Fermenter, Drip-Flow Reactor
Defined-Species Biofilm	<i>S. oralis</i> and <i>A. oris</i> biofilm growth was enhanced when co-cultured compared to when alone (Palmer et al. 2001).	<i>C. albicans</i> , <i>L. casei</i> , <i>S. mutans</i> mixed-species biofilm growth inhibited 10-fold on MRD coupons containing fluoride compared to coupons containing no fluoride.	Flowcells, Modified Robbins Device
Microcosm Biofilm	Community composition of <i>in vitro</i> biofilms can reflect that of microcosm donor (McBain et al. 2005).	Nisin retarded multi-species biofilm development without cytotoxicity to human cells (Shin et al. 2015).	Sorbarod Perfusion, Bioflux™

In conclusion, the development and validation of new *in vitro* biofilm model systems for applied oral biofilm research is a continual effort, especially

with changing paradigms, perspectives, and capabilities in microbiological research techniques. The biggest challenge thus far in translating *in vitro* model system findings into clinical practice has been the difficulty to form *in vivo*-like biofilms in a laboratory setting. Enhancing older “classic” model systems or creating newer model systems and combining such models with new or improved technologies is allowing investigators to move closer to mimicking natural oral biofilm states and providing tools to measure oral biofilm outcomes more accurately.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Author's Contribution Statement

All authors contributed to the preparation of this manuscript.

**Table 1. Examples of Fundamental & Applied Research of *In Vitro* Oral Biofilms.** Studies that improve the understanding of the biology of oral biofilms are considered fundamental. Applied studies, on the other hand, are studies that focus on interventions to control oral biofilms.

658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677

\* Not an oral biofilm outcome but listed to provide historical context and highlight the shift of focus to oral biofilm outcomes.

**Table 2. Open System Biofilm Models Relevant to Oral Biofilm Research.** Examples of biofilm model systems that have been used for the study of oral biofilms. General properties of each system are described, along with each system's nutrient delivery classification, number of biofilms that can be grown per model, and volumetric scale.

Biofilm Model	Classification	General Properties	Number of Biofilms Grown Per Model <sup>x</sup>	Volumetric Range
<b>Constant depth film fermenter</b> (Peters and Wimpenny 1988)	Drip-fed	-Scraper blade to smear media and keep biofilm at constant depth -Keeps biofilm in a steady state -Rotating disc embedded with plugs -Plug composites can be modified to simulate a different substratum -Can run for weeks	<b>25</b> (Peters and Wimpenny 1988), <b>75</b> (Deng et al. 2005)	Liters
<b>Sorbarod perfusion system</b> (Hodgson et al. 1995)	Drip-fed	-Cellulose filter substratum -Media perfuses through filter material -Can run for day(s)	<b>1</b> (Hodgson et al. 1995), <b>5</b> (McBain et al. 2005)	Liters to Milliliters
<b>Drip-flow biofilm reactor</b> (Xu et al. 1998)	Drip-fed	-Reactor angled to allow drip to flow continuously across substratum -Gravity-assisted flow simulates low shear -Typically run for day(s)	<b>4-6*</b>	Liters to Milliliters
<b>Modified Robbins device</b> (McCoy et al. 1981)	Flow-fed	-Individual coupons or discs as substratum -Coupons customizable by investigator -Can run for day(s) or weeks	<b>12, 25*<sup>†</sup></b>	Liters
<b>Flowcells</b> (Palmer 1999)	Flow-fed	-Rubber or silicone spacer bound by glass coverslips -Amenable to microscopy	<b>1-4*<sup>‡</sup></b>	Liters to Milliliters

		-Can use other substrata but may be less compatible with microscopy -Typically run for a day		
<b>Bioflux™</b> (Benoit et al. 2010)	Flow-fed	- Microplates with microfluidic channels between wells -Software-controlled pneumatic pump -Glass-bottomed substratum - Used with inverted microscope -Typically run for a day	<b>3,8,24<sup>§</sup></b>	Milliliters to Microliters

\* Refers to the number of biofilms that can be grown for sampling per device and these can be in the same channel/vessel (constant depth film fermenter, modified Robbins device, or sorbarod perfusion system) or spread across multiple channels/vessels in one device (drip flow biofilm reactor, flowcells, and Bioflux™ system).

\* Commercially available through Biosurfaces Technologies Corporation.

† Commercially available through Tyler Research Corporation.

‡ Commercially available through Stovall Life Science, Inc.

§ Commercially available through Fluxion Biosciences.

**Table 3. Sequencing Platforms for 16S rRNA Community Profiling.** Compatible next-generation sequencers that have been used to characterize an oral microcosm biofilm grown *in vitro* are listed. The sequencing chemistry, expected read length, sequencing depth, and consensus accuracy of each platform is also described.

Sequencing Platform (Reference)	Sequencing Chemistry	Read Length	Sequencing Depth	Consensus Accuracy
<b>454 GS FLX*</b> (Nance et al. 2013; Kistler et al. 2015; Koopman et al. 2015)	Pyrosequencing	Up to 1000bp	700 Mb	99.997
<b>Illumina MiSeq</b> (Koopman et al. 2016) (Agnello et al. 2017)	Sequencing by synthesis	2x150, 2x250, 2x300	4.5-5.1 Gb, 7.5-8.5 Gb, 13.2-15 Gb	80% bases > 99.9 75% bases > 99.9 70% bases > 99.9
<b>Illumina HiSeq</b> (Edlund et al. 2013)	Sequencing by synthesis	2x125	450-500 Gb	80% bases > 99.9
<b>IonTorrent PGM</b> (Fernandez et al. 2017)	Ion semiconductor	Up to 400bp	Up to 2 Gb	>99.0

\* Technology is no longer supported by manufacturer.

## References

- Aas, J.A., Griffen, A.L., Dardis, S.R., Lee, A.M., Olsen, I., Dewhirst, F.E., Leys, E.J. and Paster, B.J. (2008) Bacteria of dental caries in primary and permanent teeth in children and young adults. *J Clin Microbiol* **46**, 1407-1417.
- Aas, J.A., Paster, B.J., Stokes, L.N., Olsen, I. and Dewhirst, F.E. (2005) Defining the normal bacterial flora of the oral cavity. *J Clin Microbiol* **43**, 5721-5732.

696 Abdulkareem, E.H., Memarzadeh, K., Allaker, R.P., Huang, J., Pratten, J. and Spratt, D. (2015) Anti-biofilm  
697 activity of zinc oxide and hydroxyapatite nanoparticles as dental implant coating materials. *J Dent* **43**, 1462-  
698 1469.

699 Agnello, M., Cen, L., Tran, N.C., Shi, W., McLean, J.S. and He, X. (2017) Arginine Improves pH Homeostasis  
700 via Metabolism and Microbiome Modulation. *J Dent Res* **96**, 924-930.

701 Avila, M., Ojcius, D.M. and Yilmaz, O. (2009) The oral microbiota: living with a permanent guest. *DNA Cell*  
702 *Biol* **28**, 405-411.

703 Azeredo, J., Azevedo, N.F., Briandet, R., Cerca, N., Coenye, T., Costa, A.R., Desvaux, M., Di Bonaventura, G.,  
704 Hebraud, M., Jaglic, Z., Kacaniova, M., Knochel, S., Lourenco, A., Mergulhao, F., Meyer, R.L., Nychas, G.,  
705 Simoes, M., Tresse, O. and Sternberg, C. (2017) Critical review on biofilm methods. *Critical Reviews in*  
706 *Microbiology* **43**, 313-351.

707 Azevedo, N.F., Lopes, S.P., Keevil, C.W., Pereira, M.O. and Vieira, M.J. (2009) Time to "go large" on biofilm  
708 research: advantages of an omics approach. *Biotechnol Lett* **31**, 477-485.

709 Balvociute, M. and Huson, D.H. (2017) SILVA, RDP, Greengenes, NCBI and OTT - how do these taxonomies  
710 compare? *BMC Genomics* **18**, 114.

711 Banas, J.A. and Drake, D.R. (2018) Are the mutans streptococci still considered relevant to understanding  
712 the microbial etiology of dental caries? *BMC Oral Health* **18**, 129.

713 Barb, J.J., Oler, A.J., Kim, H.S., Chalmers, N., Wallen, G.R., Cashion, A., Munson, P.J. and Ames, N.J. (2016)  
714 Development of an Analysis Pipeline Characterizing Multiple Hypervariable Regions of 16S rRNA Using  
715 Mock Samples. *PLoS One* **11**, e0148047.

716 Behjati, S. and Tarpey, P.S. (2013) What is next generation sequencing? *Arch Dis Child Educ Pract Ed* **98**,  
717 236-238.

718 Benoit, M.R., Conant, C.G., Ionescu-Zanetti, C., Schwartz, M. and Matin, A. (2010) New device for high-  
719 throughput viability screening of flow biofilms. *Appl Environ Microbiol* **76**, 4136-4142.

720 Benson, D.A., Cavanaugh, M., Clark, K., Karsch-Mizrachi, I., Ostell, J., Pruitt, K.D. and Sayers, E.W. (2018)  
721 GenBank. *Nucleic Acids Res* **46**, D41-D47.

722 Beyenal, H., Donovan, C., Lewandowski, Z. and Harkin, G. (2004) Three-dimensional biofilm structure  
723 quantification. *J Microbiol Methods* **59**, 395-413.

724 Blanc, V., Isabal, S., Sanchez, M.C., Llama-Palacios, A., Herrera, D., Sanz, M. and Leon, R. (2014)  
725 Characterization and application of a flow system for *in vitro* multispecies oral biofilm formation. *J*  
726 *Periodontal Res* **49**, 323-332.

727 Bos, R., van der Mei, H.C. and Busscher, H.J. (1996) Co-adhesion of oral microbial pairs under flow in the  
728 presence of saliva and lactose. *J Dent Res* **75**, 809-815.

729 Bradshaw, D.J., Marsh, P.D., Watson, G.K. and Allison, C. (1998) Role of *Fusobacterium nucleatum* and  
730 coaggregation in anaerobe survival in planktonic and biofilm oral microbial communities during aeration.  
731 *Infect Immun* **66**, 4729-4732.

732 Brambilla, E., Ionescu, A.C., Cazzaniga, G., Ottobelli, M., Mazzonni, A., Cadenaro, M., Gagliani, M., Tay, F.R.,  
733 Pashley, D.H., Breschi, L. (2017) *In vitro Streptococcus mutans* biofilm formation on surfaces of  
734 chlorhexidine-containing dentin bonding systems. *International Journal of Adhesion and Adhesives* **75**, 23-  
735 30.

736 Budhani, R.K. and Struthers, J.K. (1997) The use of Sorbarod biofilms to study the antimicrobial  
737 susceptibility of a strain of *Streptococcus pneumoniae*. *J Antimicrob Chemother* **40**, 601-602.

738 Bukin, Y.S., Galachyants, Y.P., Morozov, I.V., Bukin, S.V., Zakharenko, A.S. and Zemskaia, T.I. (2019) The  
739 effect of 16S rRNA region choice on bacterial community metabarcoding results. *Sci Data* **6**, 190007.

740 Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello, E.K., Fierer, N., Pena,  
741 A.G., Goodrich, J.K., Gordon, J.I., Huttley, G.A., Kelley, S.T., Knights, D., Koenig, J.E., Ley, R.E., Lozupone,  
742 C.A., McDonald, D., Muegge, B.D., Pirrung, M., Reeder, J., Sevinsky, J.R., Turnbaugh, P.J., Walters, W.A.,  
743 Widmann, J., Yatsunenkov, T., Zaneveld, J. and Knight, R. (2010) QIIME allows analysis of high-throughput  
744 community sequencing data. *Nat Methods* **7**, 335-336.

745 Chakravorty, S., Helb, D., Burday, M., Connell, N. and Alland, D. (2007) A detailed analysis of 16S ribosomal  
746 RNA gene segments for the diagnosis of pathogenic bacteria. *J Microbiol Methods* **69**, 330-339.

747 Cieplik, F., Zaura, E., Brandt, B.W., Buijs, M.J., Buchalla, W., Crielaard, W., Laine, M.L., Deng, D.M. and  
748 Exterkate, R.A.M. (2019) Microcosm biofilms cultured from different oral niches in periodontitis patients. *J*  
749 *Oral Microbiol* **11**, 1551596.

750 Clarridge, J.E., 3rd (2004) Impact of 16S rRNA gene sequence analysis for identification of bacteria on  
751 clinical microbiology and infectious diseases. *Clin Microbiol Rev* **17**, 840-862, table of contents.

752 Coenye, T., De Prijck, K., De Wever, B. and Nelis, H.J. (2008) Use of the modified Robbins device to study  
753 the *in vitro* biofilm removal efficacy of NitrAdine, a novel disinfecting formula for the maintenance of oral  
754 medical devices. *J Appl Microbiol* **105**, 733-740.

755 Coenye, T. and Nelis, H.J. (2010) *In vitro* and *in vivo* model systems to study microbial biofilm formation. *J*  
756 *Microbiol Methods* **83**, 89-105.

757 Corbin, A., Pitts, B., Parker, A. and Stewart, P.S. (2011) Antimicrobial penetration and efficacy in an *in vitro*  
758 oral biofilm model. *Antimicrobial agents and chemotherapy* **55**, 3338-3344.

759 Cuadra-Saenz, G., Rao, D.L., Underwood, A.J., Belapure, S.A., Campagna, S.R., Sun, Z., Tammariello, S. and  
760 Rickard, A.H. (2012) Autoinducer-2 influences interactions amongst pioneer colonizing streptococci in oral  
761 biofilms. *Microbiology* **158**, 1783-1795.

762 de Chaumont, F., Dallongeville, S., Chenouard, N., Herve, N., Pop, S., Provoost, T., Meas-Yedid, V.,  
763 Pankajakshan, P., Lecomte, T., Le Montagner, Y., Lagache, T., Dufour, A. and Olivo-Marin, J.C. (2012) Icy: an  
764 open bioimage informatics platform for extended reproducible research. *Nat Methods* **9**, 690-696.

765 Deng, D.M. and ten Cate, J.M. (2004) Demineralization of dentin by *Streptococcus mutans* biofilms grown  
766 in the constant depth film fermentor. *Caries Res* **38**, 54-61.

767 Deng, D.M., van Loveren, C. and ten Cate, J.M. (2005) Caries-preventive agents induce remineralization of  
768 dentin in a biofilm model. *Caries Res* **39**, 216-223.

769 Dibdin, G.H., Shellis, R.P. and Wilson, C.M. (1976) An apparatus for the continuous culture of micro-  
770 organisms on solid surfaces with special reference to dental plaque. *J Appl Bacteriol* **40**, 261-268.

771 Dietz, V.H. (1943) *In vitro* production of plaques and caries. *Journal of Dental Research* **22**, 423-440.

772 Ding, A.M., Palmer, R.J., Jr., Cisar, J.O. and Kolenbrander, P.E. (2010) Shear-enhanced oral microbial  
773 adhesion. *Appl Environ Microbiol* **76**, 1294-1297.

774 Ding, Y., Wang, W., Fan, M., Tong, Z., Kuang, R., Jiang, W. and Ni, L. (2014) Antimicrobial and anti-biofilm  
775 effect of Bac8c on major bacteria associated with dental caries and *Streptococcus mutans* biofilms.  
776 *Peptides* **52**, 61-67.

777 Dong, L., Tong, Z., Linghu, D., Lin, Y., Tao, R., Liu, J., Tian, Y. and Ni, L. (2012) Effects of sub-minimum  
778 inhibitory concentrations of antimicrobial agents on *Streptococcus mutans* biofilm formation. *Int J*  
779 *Antimicrob Agents* **39**, 390-395.

780 Edlund, A., Yang, Y., Hall, A.P., Guo, L., Lux, R., He, X., Nelson, K.E., Nealson, K.H., Yooseph, S., Shi, W. and  
781 McLean, J.S. (2013) An *in vitro* biofilm model system maintaining a highly reproducible species and  
782 metabolic diversity approaching that of the human oral microbiome. *Microbiome* **1**, 25.

783 Elliott, D., Pratten, J., Edwards, M., Crowther, J., Petrie, A. and Wilson, M. (2005) Bacterial biofilm  
784 development on hydroxyapatite-coated glass. *Curr Microbiol* **51**, 41-45.

785 Fan, Y., Wen, Z.T., Liao, S., Lallier, T., Hagan, J.L., Twomley, J.T., Zhang, J.F., Sun, Z. and Xu, X. (2012) Novel  
786 amelogenin-releasing hydrogel for remineralization of enamel artificial caries. *J Bioact Compat Polym* **27**,  
787 585-603.

788 Feldman, M., Shenderovich, J., Lavy, E., Friedman, M. and Steinberg, D. (2017) A Sustained-Release  
789 Membrane of Thiazolidinedione-8: Effect on Formation of a Candida/Bacteria Mixed Biofilm on  
790 Hydroxyapatite in a Continuous Flow Model. *Biomed Res Int* **2017**, 3510124.

791 Fernandez, C.E., Aspiras, M.B., Dodds, M.W., Gonzalez-Cabezas, C. and Rickard, A.H. (2017) The effect of  
792 inoculum source and fluid shear force on the development of *in vitro* oral multispecies biofilms. *J Appl*  
793 *Microbiol* **122**, 796-808.

794 Fernandez, C.E., Tenuta, L.M. and Cury, J.A. (2016) Validation of a Cariogenic Biofilm Model to Evaluate the  
795 Effect of Fluoride on Enamel and Root Dentine Demineralization. *PLoS One* **11**, e0146478.

796 Foster, J.S. and Kolenbrander, P.E. (2004) Development of a multispecies oral bacterial community in a  
797 saliva-conditioned flow cell. *Appl Environ Microbiol* **70**, 4340-4348.

798 Foster, J.S., Pan, P.C. and Kolenbrander, P.E. (2004) Effects of antimicrobial agents on oral biofilms in a  
799 saliva-conditioned flowcell. *Biofilms* **1**, 5-12.

800 Gashti, M.P., Asselin, J., Barbeau, J., Boudreau, D. and Greener, J. (2016) A microfluidic platform with pH  
801 imaging for chemical and hydrodynamic stimulation of intact oral biofilms. *Lab Chip* **16**, 1412-1419.

802 Gibbons, R.J. and Fitzgerald, R.J. (1969) Dextran-induced agglutination of *Streptococcus mutans*, and its  
803 potential role in the formation of microbial dental plaques. *J Bacteriol* **98**, 341-346.

804 Goeres, D.M., Hamilton, M.A., Beck, N.A., Buckingham-Meyer, K., Hilyard, J.D., Loetterle, L.R., Lorenz, L.A.,  
805 Walker, D.K. and Stewart, P.S. (2009) A method for growing a biofilm under low shear at the air-liquid  
806 interface using the drip flow biofilm reactor. *Nat Protoc* **4**, 783-788.

807 Gomes, I.B., Meireles, A., Goncalves, A.L., Goeres, D.M., Sjollem, J., Simoes, L.C. and Simoes, M. (2018)  
808 Standardized reactors for the study of medical biofilms: a review of the principles and latest modifications.  
809 *Crit Rev Biotechnol* **38**, 657-670.

810 Guggenheim, B., Gmur, R., Galicia, J.C., Stathopoulou, P.G., Benakanakere, M.R., Meier, A., Thurnheer, T.  
811 and Kinane, D.F. (2009) *In vitro* modeling of host-parasite interactions: the 'subgingival' biofilm challenge of  
812 primary human epithelial cells. *BMC Microbiol* **9**, 280.

813 Hajishengallis, G., Darveau, R.P. and Curtis, M.A. (2012) The keystone-pathogen hypothesis. *Nat Rev*  
814 *Microbiol* **10**, 717-725.

815 Heydorn, A., Nielsen, A.T., Hentzer, M., Sternberg, C., Givskov, M., Ersboll, B.K. and Molin, S. (2000)  
816 Quantification of biofilm structures by the novel computer program COMSTAT. *Microbiology* **146** ( Pt 10),  
817 2395-2407.

818 Hodgson, A.E., Nelson, S.M., Brown, M.R. and Gilbert, P. (1995) A simple *in vitro* model for growth control  
819 of bacterial biofilms. *J Appl Bacteriol* **79**, 87-93.

820 Hojo, K., Nagaoka, S., Ohshima, T. and Maeda, N. (2009) Bacterial interactions in dental biofilm  
821 development. *J Dent Res* **88**, 982-990.

822 Honraet, K. and Nelis, H.J. (2006) Use of the modified robbins device and fluorescent staining to screen  
823 plant extracts for the inhibition of *S. mutans* biofilm formation. *J Microbiol Methods* **64**, 217-224.

824 Hope, C.K., Bakht, K., Burnside, G., Martin, G.C., Burnett, G., de Josselin de Jong, E. and Higham, S.M.  
825 (2012) Reducing the variability between constant-depth film fermenter experiments when modelling oral  
826 biofilm. *J Appl Microbiol* **113**, 601-608.

827 Hope, C.K., Clements, D. and Wilson, M. (2002) Determining the spatial distribution of viable and nonviable  
828 bacteria in hydrated microcosm dental plaques by viability profiling. *J Appl Microbiol* **93**, 448-455.

829 Janda, J.M. and Abbott, S.L. (2007) 16S rRNA gene sequencing for bacterial identification in the diagnostic  
830 laboratory: pluses, perils, and pitfalls. *J Clin Microbiol* **45**, 2761-2764.

831 Kankaanpaa, P., Paavolainen, L., Tiitta, S., Karjalainen, M., Paivarinne, J., Nieminen, J., Marjomaki, V.,  
832 Heino, J. and White, D.J. (2012) BioImageXD: an open, general-purpose and high-throughput image-  
833 processing platform. *Nat Methods* **9**, 683-689.

834 Keyes, P.H. (1968) Research in dental caries. *J Am Dent Assoc* **76**, 1357-1373.

835 Kim, D., Barraza, J.P., Arthur, R.A., Hara, A., Lewis, K., Liu, Y., Scisci, E.L., Hajishengallis, E., Whiteley, M. and  
836 Koo, H. (2020) Spatial mapping of polymicrobial communities reveals a precise biogeography associated  
837 with human dental caries. *Proc Natl Acad Sci U S A* **117**, 12375-12386.

838 Kinniment, S.L., Wimpenny, J.W., Adams, D. and Marsh, P.D. (1996) Development of a steady-state oral  
839 microbial biofilm community using the constant-depth film fermenter. *Microbiology* **142 ( Pt 3)**, 631-638.

840 Kistler, J.O., Pesaro, M. and Wade, W.G. (2015) Development and pyrosequencing analysis of an in-vitro  
841 oral biofilm model. *BMC Microbiol* **15**, 24.

842 Klug, B., Santigli, E., Westendorf, C., Tangl, S., Wimmer, G. and Grube, M. (2016) From Mouth to Model:  
843 Combining *in vivo* and *in vitro* Oral Biofilm Growth. *Front Microbiol* **7**, 1448.

844 Kolenbrander, P.E. (2011) Multispecies communities: interspecies interactions influence growth on saliva  
845 as sole nutritional source. *Int J Oral Sci* **3**, 49-54.

846 Kolenbrander, P.E., Palmer, R.J., Jr., Rickard, A.H., Jakubovics, N.S., Chalmers, N.I. and Diaz, P.I. (2006)  
847 Bacterial interactions and successions during plaque development. *Periodontol 2000* **42**, 47-79.

848 Konstantinidis, K.T. and Tiedje, J.M. (2007) Prokaryotic taxonomy and phylogeny in the genomic era:  
849 advancements and challenges ahead. *Curr Opin Microbiol* **10**, 504-509.

850 Koopman, J.E., Buijs, M.J., Brandt, B.W., Keijser, B.J., Crielaard, W. and Zaura, E. (2016) Nitrate and the  
851 Origin of Saliva Influence Composition and Short Chain Fatty Acid Production of Oral Microcosms. *Microb*  
852 *Ecol* **72**, 479-492.

853 Koopman, J.E., Roling, W.F., Buijs, M.J., Sissons, C.H., ten Cate, J.M., Keijser, B.J., Crielaard, W. and Zaura, E.  
854 (2015) Stability and resilience of oral microcosms toward acidification and *Candida* outgrowth by arginine  
855 supplementation. *Microb Ecol* **69**, 422-433.

856 Lamont, E.I., Gadkari, A., Kerns, K.A., To, T.T., Daubert, D., Kotsakis, G., Bor, B., He, X. and McLean, J.S.  
857 (2021) Modified SHI medium supports growth of a disease-state subgingival polymicrobial community *in*  
858 *vitro*. *Mol Oral Microbiol* **36**, 37-49.

859 Lamont, R.J., Koo, H. and Hajishengallis, G. (2018) The oral microbiota: dynamic communities and host  
860 interactions. *Nat Rev Microbiol* **16**, 745-759.

861 Lawrence, J.R., Korber, D.R., Hoyle, B.D., Costerton, J.W. and Caldwell, D.E. (1991) Optical sectioning of  
862 microbial biofilms. *J Bacteriol* **173**, 6558-6567.



863 Ledder, R.G. and McBain, A.J. (2012) An in vitro comparison of dentifrice formulations in three distinct oral  
864 microbiotas. *Arch Oral Biol* **57**, 139-147.

865 Ledder, R.G., Sreenivasan, P.K., DeVizio, W. and McBain, A.J. (2010) Evaluation of the specificity and  
866 effectiveness of selected oral hygiene actives in salivary biofilm microcosms. *J Med Microbiol* **59**, 1462-  
867 1468.

868 Li, Y., Zou, C.G., Fu, Y., Li, Y., Zhou, Q., Liu, B., Zhang, Z. and Liu, J. (2016) Oral microbial community typing  
869 of caries and pigment in primary dentition. *BMC Genomics* **17**, 558.

870 Listgarten, M.A. (1965) Electron Microscopic Observations on the Bacterial Flora of Acute Necrotizing  
871 Ulcerative Gingivitis. *J Periodontol* **36**, 328-339.

872 Luo, T.L., Eisenberg, M.C., Hayashi, M.A.L., Gonzalez-Cabezas, C., Foxman, B., Marrs, C.F. and Rickard, A.H.  
873 (2018) A Sensitive Thresholding Method for Confocal Laser Scanning Microscope Image Stacks of Microbial  
874 Biofilms. *Sci Rep* **8**, 13013.

875 Luo, T.L., Hayashi, M., Zsiska, M., Circello, B., Eisenberg, M., Gonzalez-Cabezas, C., Foxman, B., Marrs, C.F.  
876 and Rickard, A.H. (2019) Introducing BAIT (Biofilm Architecture Inference Tool): a software program to  
877 evaluate the architecture of oral multi-species biofilms. *Microbiology* **165**, 527-537.

878 Marsh, P.D. (2009) Role of the Oral Microflora in Health. *Microbial Ecology in Health and Disease* **12**, 130-  
879 137.

880 Marsh, P.D. (2010) Controlling the oral biofilm with antimicrobials. *J Dent* **38 Suppl 1**, S11-15.

881 Marsh, P.D. (2018) In Sickness and in Health-What Does the Oral Microbiome Mean to Us? An Ecological  
882 Perspective. *Adv Dent Res* **29**, 60-65.

883 Martin-Kerry, J.M., Lamont, T.J., Keightley, A., Calache, H., Martin, R., Floate, R., Princi, K. and de Silva, A.M.  
884 (2015) Practical considerations for conducting dental clinical trials in primary care. *Br Dent J* **218**, 629-634.

885 McBain, A.J. (2009) Chapter 4: *In vitro* biofilm models: an overview. *Adv Appl Microbiol* **69**, 99-132.

886 McBain, A.J., Bartolo, R.G., Catrenich, C.E., Charbonneau, D., Ledder, R.G. and Gilbert, P. (2003) Growth  
887 and molecular characterization of dental plaque microcosms. *J Appl Microbiol* **94**, 655-664.

888 McBain, A.J., Sissons, C., Ledder, R.G., Sreenivasan, P.K., De Vizio, W. and Gilbert, P. (2005) Development  
889 and characterization of a simple perfused oral microcosm. *J Appl Microbiol* **98**, 624-634.

890 McCall, A. and Edgerton, M. (2017) Real-Time Approach to Flow Cell Imaging of *Candida albicans* Biofilm  
891 Development. *J Fungi (Basel)* **3**.

892 McCoy, W.F., Bryers, J.D., Robbins, J. and Costerton, J.W. (1981) Observations of fouling biofilm formation.  
893 *Can J Microbiol* **27**, 910-917.

894 McNamara, G., Difilippantonio, M., Ried, T. and Bieber, F.R. (2017) Microscopy and Image Analysis. *Curr*  
895 *Protoc Hum Genet* **94**, 4 4 1-4 4 89.

896 Metcalf, D., Robinson, C., Devine, D. and Wood, S. (2006) Enhancement of erythrosine-mediated  
897 photodynamic therapy of *Streptococcus mutans* biofilms by light fractionation. *J Antimicrob Chemother* **58**,  
898 190-192.

899 Mira, A. (2018) Oral Microbiome Studies: Potential Diagnostic and Therapeutic Implications. *Adv Dent Res*  
900 **29**, 71-77.

901 Mukherjee, C., Beall, C.J., Griffen, A.L. and Leys, E.J. (2018) High-resolution ISR amplicon sequencing reveals  
902 personalized oral microbiome. *Microbiome* **6**, 153.

903 Nagaoka, S., Hojo, K., Murata, S., Mori, T., Ohshima, T. and Maeda, N. (2008) Interactions between salivary  
904 *Bifidobacterium adolescentis* and other oral bacteria: *in vitro* coaggregation and coadhesion assays. *FEMS*  
905 *Microbiol Lett* **281**, 183-189.

906 Nance, W.C., Dowd, S.E., Samarian, D., Chludzinski, J., Delli, J., Battista, J. and Rickard, A.H. (2013) A high-  
907 throughput microfluidic dental plaque biofilm system to visualize and quantify the effect of antimicrobials.  
908 *J Antimicrob Chemother* **68**, 2550-2560.

909 Negrini, T.C., Koo, H. and Arthur, R.A. (2019) Candida-Bacterial Biofilms and Host-Microbe Interactions in  
910 Oral Diseases. *Adv Exp Med Biol* **1197**, 119-141.

911 Netuschil, L., Ausschill, T.M., Sculean, A. and Arweiler, N.B. (2014) Confusion over live/dead stainings for the  
912 detection of vital microorganisms in oral biofilms--which stain is suitable? *BMC Oral Health* **14**, 2.

913 Noiri, Y., Katsumoto, T., Azakami, H. and Ebisu, S. (2008) Effects of Er:YAG laser irradiation on biofilm-  
914 forming bacteria associated with endodontic pathogens *in vitro*. *J Endod* **34**, 826-829.

915 Noorda, W.D., van Montfort, A.M., Purdell-Lewis, D.J. and Weerkamp, A.H. (1986) Developmental and  
916 metabolic aspects of a monobacterial plaque of *Streptococcus mutans* C 67-1 grown on human enamel  
917 slabs in an artificial mouth model. I. Plaque data. *Caries Res* **20**, 300-307.

918 Palmer, R.J. and Caldwell, D.E. (1995) A flowcell for the study of plaque removal and regrowth. *J Microbiol*  
919 *Methods* **24**, 171-182.

920 Palmer, R.J., Jr. (1999) Microscopy flowcells: perfusion chambers for real-time study of biofilms. *Methods*  
921 *Enzymol* **310**, 160-166.

922 Palmer, R.J., Jr., Kazmerzak, K., Hansen, M.C. and Kolenbrander, P.E. (2001) Mutualism versus  
923 independence: strategies of mixed-species oral biofilms *in vitro* using saliva as the sole nutrient source.  
924 *Infect Immun* **69**, 5794-5804.

925 Paula, A.J., Hwang, G. and Koo, H. (2020) Dynamics of bacterial population growth in biofilms resemble  
926 spatial and structural aspects of urbanization. *Nat Commun* **11**, 1354.

927 Periasamy, S. and Kolenbrander, P.E. (2009) *Aggregatibacter actinomycetemcomitans* builds mutualistic  
928 biofilm communities with *Fusobacterium nucleatum* and *Veillonella* species in saliva. *Infect Immun* **77**,  
929 3542-3551.

930 Peters, A.C. and Wimpenny, J.W. (1988) A constant-depth laboratory model film fermentor. *Biotechnol*  
931 *Bioeng* **32**, 263-270.

932 Petersen, P.E., Bourgeois, D., Ogawa, H., Estupinan-Day, S. and Ndiaye, C. (2005) The global burden of oral  
933 diseases and risks to oral health. *Bull World Health Organ* **83**, 661-669.

934 Peterson, S.N., Snesrud, E., Liu, J., Ong, A.C., Kilian, M., Schork, N.J. and Bretz, W. (2013) The dental plaque  
935 microbiome in health and disease. *PLoS One* **8**, e58487.

936 Petti, C.A., Polage, C.R. and Schreckenberger, P. (2005) The role of 16S rRNA gene sequencing in  
937 identification of microorganisms misidentified by conventional methods. *J Clin Microbiol* **43**, 6123-6125.

938 Pigman, W., Brasher, J. and Koulourides, T. (1962) Cariogenicity of common sugars as evaluated in the  
939 artificial mouth. *Nature* **195**, 190-191.

940 Pigman, W., Elliott, H.C., Jr. and Laffre, R.O. (1952) An artificial mouth for caries research. *J Dent Res* **31**,  
941 627-633.

942 Pigman, W., Hawkins, W.L., Watson, J., Powell, R. and Gaston, C. (1955) The effect of the concentration of  
943 D-glucose on the attack of tooth substances in the artificial mouth. *J Dent Res* **34**, 537-545.

944 Pigman, W. and Newbrun, E. (1962) Evaluation of anticaries agents by the use of the artificial mouth. *J Dent*  
945 *Res* **41**, 1304-1311.

946 Pratten, J., Wills, K., Barnett, P. and Wilson, M. (1998) *In vitro* studies of the effect of antiseptic-containing  
947 mouthwashes on the formation and viability of *Streptococcus sanguis* biofilms. *J Appl Microbiol* **84**, 1149-  
948 1155.

949 Rickard, A.H., Campagna, S.R. and Kolenbrander, P.E. (2008) Autoinducer-2 is produced in saliva-fed flow  
950 conditions relevant to natural oral biofilms. *J Appl Microbiol* **105**, 2096-2103.

951 Roder, H.L., Olsen, N.M.C., Whiteley, M. and Burmolle, M. (2020) Unravelling interspecies interactions  
952 across heterogeneities in complex biofilm communities. *Environ Microbiol* **22**, 5-16.

953 Ruangcharoen, S., Suwannarong, W., Lachica, M., Bolscher, J.G.M., Nazmi, K., Khunkitti, W. and  
954 Taweekaisupapong, S. (2017) Killing activity of LFchimera on periodontopathic bacteria and multispecies  
955 oral biofilm formation *in vitro*. *World J Microbiol Biotechnol* **33**, 167.

956 Rudney, J.D., Chen, R., Lenton, P., Li, J., Li, Y., Jones, R.S., Reilly, C., Fok, A.S. and Aparicio, C. (2012) A  
957 reproducible oral microcosm biofilm model for testing dental materials. *J Appl Microbiol* **113**, 1540-1553.

958 Russell, C. and Coulter, W.A. (1975) Continuous monitoring of pH and Eh in bacterial plaque grown on a  
959 tooth in an artificial mouth. *Appl Microbiol* **29**, 141-144.

960 Russell, C. and Coulter, W.A. (1977) Plaque formation by streptococci in an artificial mouth and factors  
961 influencing colonization. *J Appl Bacteriol* **42**, 337-344.

962 Sackmann, E.K., Fulton, A.L. and Beebe, D.J. (2014) The present and future role of microfluidics in  
963 biomedical research. *Nature* **507**, 181-189.

964 Samarian, D.S., Jakubovics, N.S., Luo, T.L. and Rickard, A.H. (2014) Use of a high-throughput *in vitro*  
965 microfluidic system to develop oral multi-species biofilms. *J Vis Exp*.

966 Shin, J.M., Ateia, I., Paulus, J.R., Liu, H., Fenno, J.C., Rickard, A.H. and Kapila, Y.L. (2015) Antimicrobial nisin  
967 acts against saliva derived multi-species biofilms without cytotoxicity to human oral cells. *Front Microbiol*  
968 **6**, 617.

969 Sissons, C.H. (1997) Artificial dental plaque biofilm model systems. *Adv Dent Res* **11**, 110-126.

970 Sissons, C.H., Cutress, T.W., Hoffman, M.P. and Wakefield, J.S. (1991) A multi-station dental plaque  
971 microcosm (artificial mouth) for the study of plaque growth, metabolism, pH, and mineralization. *J Dent*  
972 *Res* **70**, 1409-1416.

973 Sissons, C.H., Cutress, T.W. and Pearce, E.I. (1985) Kinetics and product stoichiometry of ureolysis by  
974 human salivary bacteria and artificial mouth plaques. *Arch Oral Biol* **30**, 781-790.

975 Sissons, C.H., Wong, L. and An, Y.H. (2000) Laboratory Culture and Analysis of Microbial Biofilms. In  
976 *Handbook of Bacterial Adhesion: Principles, Methods, and Applications* eds. An, Y.H. and Friedman, R.J.  
977 pp.133-169. Totowa, NJ: Humana Press.

978 Sliepen, I., Van Essche, M., Quirynen, M. and Teughels, W. (2010) Effect of mouthrinses on *Aggregatibacter*  
979 *actinomycetemcomitans* biofilms in a hydrodynamic model. *Clin Oral Investig* **14**, 241-250.

980 Spencer, P., Greenman, J., McKenzie, C., Gafan, G., Spratt, D. and Flanagan, A. (2007) *In vitro* biofilm model  
981 for studying tongue flora and malodour. *J Appl Microbiol* **103**, 985-992.

982 Su, C., Lu, Y. and Liu, H. (2013) Reduced TOR signaling sustains hyphal development in *Candida albicans* by  
983 lowering Hog1 basal activity. *Mol Biol Cell* **24**, 385-397.

984 Tan, C.H., Lee, K.W., Burmolle, M., Kjelleberg, S. and Rice, S.A. (2017) All together now: experimental  
985 multispecies biofilm model systems. *Environ Microbiol* **19**, 42-53.

986 Tang, G., Yip, H.K., Cutress, T.W. and Samaranayake, L.P. (2003) Artificial mouth model systems and their  
987 contribution to caries research: a review. *J Dent* **31**, 161-171.

988 Tanner, A.C., Haffer, C., Bratthall, G.T., Visconti, R.A. and Socransky, S.S. (1979) A study of the bacteria  
989 associated with advancing periodontitis in man. *J Clin Periodontol* **6**, 278-307.

990 Tao, R., Tong, Z., Lin, Y., Xue, Y., Wang, W., Kuang, R., Wang, P., Tian, Y. and Ni, L. (2011) Antimicrobial and  
991 antibiofilm activity of pleurocidin against cariogenic microorganisms. *Peptides* **32**, 1748-1754.

992 Teng, F., Darveekaran Nair, S.S., Zhu, P., Li, S., Huang, S., Li, X., Xu, J. and Yang, F. (2018) Impact of DNA  
993 extraction method and targeted 16S-rRNA hypervariable region on oral microbiota profiling. *Sci Rep* **8**,  
994 16321.

995 Thurnheer, T., Karygianni, L., Flury, M. and Belibasakis, G.N. (2019) *Fusobacterium* Species and Subspecies  
996 Differentially Affect the Composition and Architecture of Supra- and Subgingival Biofilms Models. *Front*  
997 *Microbiol* **10**, 1716.

998 Tian, Y., He, X., Torralba, M., Yooseph, S., Nelson, K.E., Lux, R., McLean, J.S., Yu, G. and Shi, W. (2010) Using  
999 DGGE profiling to develop a novel culture medium suitable for oral microbial communities. *Mol Oral*  
000 *Microbiol* **25**, 357-367.

001 Tsutsumi, C., Takakuda, K. and Wakabayashi, N. (2016) Reduction of Candida biofilm adhesion by  
002 incorporation of prereacted glass ionomer filler in denture base resin. *J Dent* **44**, 37-43.

003 Valm, A.M., Mark Welch, J.L. and Borisy, G.G. (2012) CLASI-FISH: principles of combinatorial labeling and  
004 spectral imaging. *Syst Appl Microbiol* **35**, 496-502.

005 Velsko, I.M. and Shaddox, L.M. (2018) Consistent and reproducible long-term *in vitro* growth of health and  
006 disease-associated oral subgingival biofilms. *BMC Microbiol* **18**, 70.

007 Vogtmann, E., Hua, X., Zhou, L., Wan, Y., Suman, S., Zhu, B., Dagnall, C.L., Hutchinson, A., Jones, K., Hicks,  
008 B.D., Sinha, R., Shi, J. and Abnet, C.C. (2018) Temporal variability of oral microbiota over 10 months and the  
009 implications for future epidemiologic studies. *Cancer Epidemiol Biomarkers Prev*.

010 Volgenant, C.M., Hoogenkamp, M.A., Krom, B.P., Janus, M.M., Ten Cate, J.M., de Soet, J.J., Crielaard, W.  
011 and van der Veen, M.H. (2016) Red and Green Fluorescence from Oral Biofilms. *PLoS One* **11**, e0168428.

012 Vos, T. and Collaborators, G.D.a.I.I.P. (2017) Global, regional, and national incidence, prevalence, and years  
013 lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the  
014 Global Burden of Disease Study 2016. *Lancet* **390**, 1211-1259.

015 Wade, W.G. and Prosdocimi, E.M. (2020) Profiling of Oral Bacterial Communities. *J Dent Res* **99**, 621-629.

016 Walker, C. and Sedlacek, M.J. (2007) An *in vitro* biofilm model of subgingival plaque. *Oral Microbiol*  
017 *Immunol* **22**, 152-161.

018 Weisburg, W.G., Barns, S.M., Pelletier, D.A. and Lane, D.J. (1991) 16S ribosomal DNA amplification for  
019 phylogenetic study. *J Bacteriol* **173**, 697-703.

020 Whitmore, S.E. and Lamont, R.J. (2011) The pathogenic persona of community-associated oral  
021 streptococci. *Mol Microbiol* **81**, 305-314.

022 Williams, D.L., Epperson, R.T., DeGrauw, J.P., Nielsen, M.B., Taylor, N.B. and Jolley, R.D. (2017) Effect of  
023 silver-loaded PMMA on *Streptococcus mutans* in a drip flow reactor. *J Biomed Mater Res A* **105**, 2632-2639.

024 Woese, C.R. and Fox, G.E. (1977) Phylogenetic structure of the prokaryotic domain: the primary kingdoms.  
025 *Proc Natl Acad Sci U S A* **74**, 5088-5090.

026 Wong, L., Sissons, C.H. and Cutress, T.W. (1994) Control of multiple dental plaque culture system and long-  
027 term, continuous, plaque pH measurement using LabVIEW. *Binary* **6**, 173-180.

028 Wright, T.L., Ellen, R.P., Lacroix, J.M., Sinnadurai, S. and Mittelman, M.W. (1997) Effects of metronidazole  
029 on *Porphyromonas gingivalis* biofilms. *J Periodontal Res* **32**, 473-477.

030 Xu, K.D., Stewart, P.S., Xia, F., Huang, C.T. and McFeters, G.A. (1998) Spatial physiological heterogeneity in  
031 *Pseudomonas aeruginosa* biofilm is determined by oxygen availability. *Appl Environ Microbiol* **64**, 4035-  
032 4039.

033 Yaari, A. and Bibby, B.G. (1976) Production of plaques and initiation of caries *in vitro*. *J Dent Res* **55**, 30-36.

034 Yassin, S.A., German, M.J., Rolland, S.L., Rickard, A.H. and Jakubovics, N.S. (2016) Inhibition of multispecies  
035 biofilms by a fluoride-releasing dental prosthesis copolymer. *J Dent* **48**, 62-70.


036 Yu, O.Y., Zhao, I.S., Mei, M.L., Lo, E.C. and Chu, C.H. (2017) Dental Biofilm and Laboratory Microbial Culture  
037 Models for Cariology Research. *Dent J (Basel)* **5**.

038 Zanin, I.C., Goncalves, R.B., Junior, A.B., Hope, C.K. and Pratten, J. (2005) Susceptibility of *Streptococcus*  
039 *mutans* biofilms to photodynamic therapy: an *in vitro* study. *J Antimicrob Chemother* **56**, 324-330.


040 Zaura-Arite, E., van Marle, J. and ten Cate, J.M. (2001) Confocal microscopy study of undisturbed and  
041 chlorhexidine-treated dental biofilm. *J Dent Res* **80**, 1436-1440.

042

043 **Fig 1.** Diagram showing different types of drip reactors and flow reactors described in this review. These  
044 have been, or could conceptually be, integrated with a confocal microscope to image biofilms in 3D at the  
045 end of an experiment (“Endpoint Confocal Microscopy”) and/or image repeatedly in 3D over time during an  
046 experiment for spatiotemporal analyses (“Live Confocal Microscopy”). Both confocal microscopy  
047 approaches have the potential for the spatial analysis of single or multiple species. Some of these systems  
048 have or could also conceivably be combined with culture-dependent approaches and/or culture-  
049 independent techniques to study the community composition of oral biofilms.



050



jam\_15200\_f1.jpg